Stock Ticker

  • Loading stock data...

Boston Scientific Corporation (NYSE:BSX) – May Reach $20 If Bulls Protect $17 Levels

Boston Scientific Corporation (NYSE:BSX) spent a flat session last Friday, ending the session with a meager loss of 0.45%. It was the fourth consecutive session in the narrow range of $17-$18 and the stock still keeps the hopes of further rally alive. Boston Scientific Corporation (NYSE:BSX) announced the first quarter earnings result last Tuesday and […]

Boston Scientific Corporation (NYSE:BSX) Set to Develop a Strategic Partnership in China

Boston Scientific Corporation (NYSE:BSX) has reached a strategic alliance with Frankenman Medical Equipment in China. The deal allows Boston Scientific to tap in the vast market of surgical equipment in China. The two companies have also agreed to increase clinical awareness about less invasive endoscopic methods. The object of increased awareness is to make the […]

Boston Scientific Corporation (NYSE:BSX) Gets Part Relief From Court On Mesh Punitive Damages

Boston, MA 10/06/2014 (wallstreetpr) – Boston Scientific Corporation (NYSE:BSX) could derive some solace from a District Court order. The court has slashed the punitive damages to less than half in the case filed by women on the company’s vaginal mesh implants. Reduced Damages In the third trial heard on the company’s product, a Texas Judge reduced […]

Boston Scientific Corporation (NYSE:BSX) Asked To Pay $308 Million In Patent Infringement Case

Boston, MA 09/26/2014 (wallstreetpr) – Boston Scientific Corporation (NYSE:BSX) announced receiving a negative decree from a court that demands the company to pay as much as $308 million in patent infringement case. Unfavorable Verdict According to an article, the medical equipment manufacturer has been ruled to pay the sum of $308 million on pretext of […]

Boston Scientific Corporation (NYSE:BSX)’s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus™ Valve System

Boston, MA 09/17/2014 (wallstreetpr) – The clinical trial of Lotus™ Valve System of Boston Scientific Corporation (NYSE:BSX) is enduringly proving its performance in terms of being the less persistent treatment for aortic stenosis patients. The company released new data, according to which the performance is demonstrated to be strong for patients who are at high […]

Goldman Sachs Group Inc (NYSE:GS) Key Takeaways from Transcatheter Cardiovascular Therapeutics Conference

Boston, MA 09/16/2014 (wallstreetpr) – Investment advisor, Goldman Sachs Group Inc (NYSE:GS) analysts have provided key takeaways from the 2014 Transcatheter Cardiovascular Therapeutics or TPT conference. Accordingly, they have retained their Buy rating on the shares of Abbott Pharmaceuticals (NYSE:ABT) and Edwards Lifesciences Corp (NYSE:EW) while they remained Neutral on St. Jude Medical, Inc. (NYSE:STJ) […]

Boston Scientific Corporation (NYSE:BSX) To Present Data At Transcatheter Cardiovascular Therapeutics Meeting To Reinforce Its Commitment On Interventional Cardiology

Boston, MA 09/11/2014 (wallstreetpr) – Medical device manufacturer, Boston Scientific Corporation (NYSE:BSX) would present data at the 26th Transcatheter Cardiovascular Therapeutics or TCT meeting to reinforce its commitment towards the development of innovative treatment in interventional cardiology. Results To Be Shared Boston Scientific Corporation (NYSE:BSX) disclosed that it would share the results from over a dozen […]

WallFlex Biliary RX Stent Study Conducted by Boston Scientific Corporation (NYSE:BSX) Leads to a Successful End

Boston, MA 09/03/2014 (wallstreetpr) – As per the reports, Boston Scientific Corporation (NYSE:BSX) has released the results of WallFlex Biliary RX Stent study which was conducted by the company some time back. The study led to positive results that have been published in the latest issue of prominent journal Gastroenterology. Primary purpose of study: The […]

Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX)

Boston, MA 09/02/2014 (wallstreetpr) – Primary endpoints results of the clinical trial of Neural Cardiac Therapy for Heart Failure (NECTAR-HF) were released by Boston Scientific Corporation (NYSE:BSX) recently. The company called this as the one-of-its-kind sham-controlled test based on a random basis and looking into Vagus Nerve Stimulation (VNS) for the heart failure patients. The […]

Law Offices of Howard G. Smith To Start Investigation on Behalf of Boston Scientific Corporation (NYSE:BSX)

Boston, MA 08/11/2014 (wallstreetpr) – According to reports, Law Offices of Howard G. Smith have decided to conduct an investigation about potential claims on behalf of Boston Scientific Corporation (NYSE:BSX). In the recent past, BSX raised several statements regarding violation of federal security laws; hence, the investigation is supposed to address all those issues. What’s the […]

Boston Scientific Corporation (NYSE:BSX) Innovating to the State of the Art Technologies CE Mark for Ranger™ Drug-Coated Balloon

Boston, MA 07/25/2014 (wallstreetpr) – Boston Scientific Corporation (NYSE:BSX) has acquired CE mark, a European Union approval, for its latest product Ranger™ Drug Coated Balloon (RDCB) used in treatment of peripheral artery disease (PAD). This product enables physicians to treat PAD related diseases by delivering the anti stenotic drug to vascular tissue without leaving any permanent […]

Boston Scientific Corporation (NYSE:BSX)’s Vercise DBS System Display Significant Improvement In 1-Year Study Results

Boston, MA 06/16/2014 (wallstreetpr) – Medical technology company, Boston Scientific corporation (NYSE:BSX) disclosed that the treatment given to Parkinson disease patients with its Vercise Deep Brain stimulation or DBS process displayed a consistent and significant improvement in motor scores during the one-year results of the vantage clinical trial evaluation. Favorable Results The company presented the data […]

Boston Scientific Corporation’s (NYSE:BSX) Vercise success

Boston, MA 06/12/2014 (wallstreetpr) – Boston Scientific Corporation’s (NYSE:BSX) system developed for the treatment of Parkinson’s disease has successfully demonstrated an improving effect on patients who got treated with the same. Boston’s Vercise™ Deep Brain Stimulation (DBS) has shown that compared to conventional pulses, shorter simulation pulses may prove to be more effective. Vercise™ Deep Brain Stimulation (DBS) […]

Boston Scientific Corporation (NYSE:BSX) On Track To Drive Growth From MedSurg Unit

Boston, MA 06/12/2014 (wallstreetpr) – Medical technology device maker Boston Scientific Corporation (NYSE:BSX) has indicated that it is on track to maintain expanding the sales mix overall and get the robust upside from its MedSurg unit. It is a resultant of market development efforts, as well as, global expansion. Bottom Line The company presented itself […]